Objective: To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) fampridine in patients with multiple sclerosis (PwMS) regarding safety, walking improvements, and changes in drug responsiveness.
Multiple sclerosis (MS) is the leading neurologic cause of persisting disability in young adults. 1 Impaired mobility due to walking deficits occurs in approximately 75% of patients with MS (PwMS) 2, 3 and is reported by these patients as the single most devastating symptom. 4, 5 Fampridine (4-aminopyridine, dalfampridine) is the only approved medication for the symptomatic treatment of gait disorders in PwMS in both the early and late phases of the disease. 6, 7 Prolonged-release (PR) fampridine blocks voltage-gated potassium channels, thereby improving signal conduction in demyelinated nerve fibers. 8, 9 Whereas beneficial effects of short-term treatment with PR fampridine on maximal walking speed [10] [11] [12] [13] [14] and additional functional outcomes 7, [13] [14] [15] (e.g., walking endurance) are wellcharacterized in PwMS, little information exists regarding the long-term safety and efficacy of therapy with PR fampridine. Open-label treatment over periods of 1 and 3 years demonstrated good tolerability and persisting improvement in ambulatory function 16 and fatigue. 7 Positive effects of PR fampridine on dynamic stability and self-perceived walking ability were further demonstrated in a double-blind, placebo-controlled study over a period of 24 weeks. 15 This study aims to expand upon the knowledge of the long-term effects of PR fampridine on walking function in PwMS. In contrast to prior long-term studies on PR fampridine, this study used annual drug holidays (open-label or placebo-controlled) to allow for accurate reassessment of drug responsiveness, thus providing important information on changes in drug efficacy over time. Given the increasing number of PwMS treated with PR fampridine for MS-related walking dysfunction, there is a pressing need for a better understanding of the long-term effects of this therapy.
METHODS Study population. This extension trial was per-
formed at the University Hospital Zurich, Switzerland, between 2013 and 2015. All participants enrolled in the trial had previously completed the core study (FAMPKIN; clinicaltrials.gov NCT01576354). Detailed inclusion and exclusion criteria of the core study are reported elsewhere. 14 No patients were excluded from the extension trial. In brief, participants diagnosed with relapsing-remitting, primary progressive, or secondary progressive MS with a clinically apparent walking impairment but able to cover a distance of at least 50 meters (with or without walking aids) in the 6-Minute Walk Test (6MWT) were included. Of 55 patients completing the core study, 53 (33 female; age 50.3 6 9.4 years; table 1) were enrolled in the extension trial.
Standard protocol approvals, registrations, and patient consents. All experimental procedures of the study (NCT01576354) were performed according to the current guidelines of the Declaration of Helsinki and Good Clinical Practice and were approved by the Zurich cantonal ethics committee and the regulatory agency for medicines (Swissmedic). All participants provided informed, written consent to enter the extension trial.
Study design. A screening visit (S) was performed at least 2 weeks after completion of the FAMPKIN core study. Based on earlier reports, 11 ,12,14 a 14-day washout period is sufficient to avoid carryover effects of PR fampridine (Biogen, Cambridge, MA). The first year of the extension trial was open-label, during which patients received 10 mg PR fampridine twice daily for 11.5 months ( figure 1A ). Long-term treatment with PR fampridine was followed by a 14-day washout phase without treatment. Patients then received continuous, long-term treatment with PR fampridine for a further 11.5 months before undergoing safety and efficacy assessments at the end of the second year in the form of a double-blind, placebo-controlled, crossover component to obviate potential placebo effects. Analogous to the open-label drug holiday in the first year, the double-blind treatment periods were limited to 14 days. At visit (V) 5, patients were randomized 1:1 into 2 groups (by the Zurich Cantonal Pharmacy), the first receiving placebo for 2 weeks followed by 2 weeks of PR fampridine with the order reversed for the second group. All experimenters and participants were blinded to the treatment allocation at the time of data assessment. Allocation concealment was removed after the last patient had completed the double-blind study visit (V7).
Study visits. Safety assessments comprising laboratory safety measures (hematology, blood chemistry, urine analysis, creatinine clearance), measurement of vital signs, reporting of adverse events (AEs) and serious AEs (SAEs), and assessment of changes in concomitant medication were performed at each study visit (figure 1B). Outcome measures relating to treatment efficacy consisted of the Timed 25-Foot Walk (T25FW), the 6MWT, and the 12-item MS Walking Scale (MSWS-12) questionnaire and were assessed at S, V2, V3, and V5 (open-label) as well as at V6 and V7 (randomized, double-blind, placebo-controlled; figure 1B). Expanded Disability Status Scale (EDSS) was assessed at S, V6, and V7. In addition to the MSWS-12, we also asked the patients to report on when they thought they were being treated with PR fampridine or with placebo to investigate whether patients perceived fampridine-induced changes additional to ambulatory improvements.
Statistical analysis. Statistical analysis was performed with SPSS (version 21, IBM, Armonk, NY). Three groups consisting of all participants, fampridine responders, and nonresponders were designated. Group classification was based on responder criteria defined in earlier publications 11, 12 and were applied based on the T25FW data of the core study. Fampridine responders were participants achieving a faster walking speed in the T25FW for at least 3 of the 4 visits during the double-blind treatment periods compared to the maximum speed recorded during any of the 5 baseline visits. The x 2 test and Fisher exact test were used to assess statistical significance of categorical variables. Statistical analysis of continuous demographic data was performed using 2-tailed, unpaired t tests. Changes in walking performance during treatment with PR fampridine or placebo were assessed by 2-tailed, paired t tests or repeated-measures 1-way analyses of variance (ANOVAs).
Classification of evidence. The primary research question was to monitor the long-term effects of PR fampridine on walking function in PwMS using 3 primary outcomes consisting of 2 quantitative clinical walking tests (T25FW, 6MWT) and the MSWS-12 questionnaire during open-label and randomized, double-blind, controlled assessments (Class II evidence).
RESULTS Fifty-three PwMS (24 relapsing-remitting, 5 primary progressive, 24 secondary progressive) with an EDSS between 3.0 and 7.0 (mean 5.3 6 1.2) were included in the extension trial (table 1) . Fortyseven patients completed the first year (30 female; age 51.4 6 9.3 years) and 36 patients (22 female; age 52.0 6 9.3 years) completed the second year of the trial. One patient was excluded from data analysis of V6 and V7 due to an elective surgical intervention between these visits. The demographics of the study population did not change over the 2 years of the extension trial (S, V3, V7; 1-way ANOVA and 2-tailed, unpaired t test for age, disease duration, EDSS; Fisher exact test for Long-term efficacy of PR fampridine on walking function. Treatment with PR fampridine resulted in improvements in walking speed (T25FW; p 5 0.0274, 1-way ANOVA) and endurance (6MWT; p 5 0.0002) across all patients and visits (figure 2A). Effects of PR fampridine in both subgroups (PR fampridine responders and nonresponders) were similar to the total population in terms of magnitude of effect, but only the improvement in 6MWT in nonresponders was statistically significant. Walking speed and endurance worsened significantly after discontinuation of study treatment for 2 weeks at the end of the first year (V2 vs V3: 211.5% in T25FW [95% confidence interval (CI) 24.9% to 218.0%]; 210.7% in 6MWT [CI 27.3% to 214.0%]). In both clinical gait tests, patients substantially recovered their walking capacity on reinitiating openlabel treatment with PR fampridine for another 11.5 months (V3 vs V5: 111.0% in T25FW [CI 3.5%-18.5%]; 113.6 in 6MWT [CI 6.8%-20.4%]). This treatment effect also remained stable during the double-blind, placebo-controlled assessment of drug efficacy: maximal walking speed improved by 13.1% (CI 4.1%-22.1%) and walking endurance by 11.9% (CI 6.4%-17.4%) during double-blind treatment with PR fampridine compared to double-blind placebo treatment. Drug efficacy in the randomized group receiving PR fampridine first was not different from that in the randomized group receiving placebo first during the double-blind treatment phase (p 5 0.2745 for T25FW, p 5 0.4339 for 6MWT, p 5 0.4313 for MSWS-12; unpaired, 2-tailed t test), indicating that the order of double-blind treatment did not influence drug efficacy. Overall walking capacity, as measured by the T25FW and 6MWT, worsened between the untreated baselines of the first year (figure 2A; S vs V3), but remained constant between baselines at the end of the first and second year in our cohort (figure 2A; V3 vs placebo). The averaged group performance while on PR fampridine (V2, V5) remained at the level of the untreated baseline (S).
Paired, statistical analysis of drug efficacy during the open-label period (V2 vs V3; figure 2B ) and the double-blind controlled treatment phases (V6 vs V7; figure 2B ) revealed significant improvements during the open-label treatment in both functional tests and all subgroups (except for nonresponders in the T25FW; paired, 2-tailed t test). Similarly, efficacy of PR fampridine during the randomized, double-blind phase was highly significant for the total population, but only reached statistical significance in the subgroup of nonresponders in the 6MWT (p 5 0.0154). Twenty-two of 31 patients correctly identified their allocation to the PR fampridine arm (p 5 0.0196; x 2 test; 5 patients declined to report).
Change in individual responsiveness to PR fampridine over time. To accurately monitor long-term efficacy of PR fampridine, we tracked the individual drug response in 33 patients who completed the FAMPKIN core study and 2 years of the extension trial ( figure 3 ). Demographic data of the 33 patients did not differ from the total populations of the core study (55 patients) or the extension trial (53 patients).
Longitudinal analysis of drug efficacy revealed that, in many participants, the response to PR fampridine changed over time ( figure 3, A and B) . Whereas overall drug efficacy as measured by the T25FW and 6MWT was not different after 2 years of PR fampridine treatment compared to short-term treatment in the core study ( figure 3C ; T25FW: 13.4%, p 5 0.3001; 6MWT: 13.9%, p 5 0.2136), self-perceived walking function improved significantly over time ( figure 3C ; MSWS-12: 25.1 points, p 5 0.0483).
To further assess patients' responsiveness to PR fampridine, we analyzed the proportion of patients exceeding a specific threshold (T25FW and 6MWT: $10% improvement; MSWS-12: #26 point improvements) in the different tests during doubleblind PR fampridine treatment of the core study and the double-blind treatment period in the extension trial. The proportion of patients improving more than 10% in walking speed was significantly higher during long-term treatment with PR fampridine compared to short-term treatment (figure 4; p 5 0.0169; Fisher exact test). Despite a similar trend in results, the proportion of patients responding in the extension trial vs the core study was not different in the 6MWT (short-term: 9/30 $10%; long-term: 15/30 $10%; p 5 0.1872) and the MSWS-12 (short-term: 10/33 #26 points; long-term: 12/33 #26 points; p 5 0.7944). While a majority of patients with substantially improved gait function on PR fampridine in the core study also showed a similar response after 2 years of long-term treatment (figures 3 and 4), more than one third of patients exhibiting no or poor initial improvements with PR fampridine in the core study changed their response to the drug and demonstrated improved walking function when tested again after 2 years ( figure 4A ). The trend towards increased responsiveness after long-term treatment was also observed for higher thresholds (i.e., 20% improvement in walking tests and 8 points in MSWS-12; figure 4B ). Fampridine-induced changes in clinical walking tests were not correlated with the self-assessed change in ambulatory performance in the double-blind core study (figure e-1 of long-term PR fampridine treatment. [15] [16] [17] The proportion of patients experiencing AEs and SAEs was in line with previous reports. 15, 16 The frequency of AEs was not different between double-blind treatment with PR fampridine and placebo, indicating that PR fampridine was likely not responsible for the AEs in PwMS treated with the drug.
Our results demonstrate significant beneficial effects of long-term treatment with PR fampridine in all tested clinical outcomes over 2 years. To prevent bias due to patients with a good drug response remaining in the trial and participants with low responsiveness dropping out, we only included patients who completed the core study and both years of the extension trial, allowing comparison of short-and longterm drug effects. Using different thresholds of effect size in the T25FW, 6MWT, and MSWS-12, we demonstrated that a considerable proportion of participants changed their response to PR fampridine over 2 years of long-term treatment. The proportion of participants reaching an improvement threshold of 10% increased from one-fifth (T25FW) and barely one-third (6MWT) to one-half of all patients (T25FW and 6MWT) after 2 years of PR fampridine treatment, a significant increase compared to shortterm, double-blinded treatment. The majority of patients (80%) who showed greater than 10% improvement in the T25FW and 6MWT in the core study maintained a similar degree of responsiveness after long-term treatment. In contrast, 40% of patients initially falling short of the 10% improvement threshold in the T25FW and 6MWT during shortterm treatment exhibited improvements $10% after 2 years. Increased responsiveness to PR fampridine in these initial poor responders, combined with a potential decline of drug efficacy in initial good responders, might explain the approximation of drug effects between responders and nonresponders seen in earlier open-label long-term studies. 16 The observed changes in drug response during long-term treatment suggest that drug efficacy should be reevaluated regularly, in particular in those patients who demonstrate a poor response to PR fampridine after initial assessment. Discussion relating to the mechanisms underlying the observed changes in responsiveness to the study drug over time must remain, for the moment, speculative. Since MS is a dynamic disease with demyelination and remyelination and axonal and neuronal death contributing to ongoing, structural alterations of the CNS gray and white matter during its course, 18 responsiveness to PR fampridine may likewise change over time. As a potassium channel blocker, it may initially improve signal conduction in demyelinated axons only to be rendered ineffective once these axons undergo degeneration with the natural course of the disease. On the other hand, appearance of new, demyelinating lesions may result in clinical deterioration amenable to improvement, at least partially and transiently, with PR fampridine treatment at that stage. Enhanced drug efficacy over time may also be the result of training effects made possible by the improved neurologic state induced by PR fampridine. Finally, the development of pharmacologic tolerance may result in a decrease in efficacy during long-term treatment. Identification of patient characteristics (e.g., type of MS, concomitant treatment) associated with changes in responsiveness to PR fampridine over time should be the focus of future, larger trials.
The effect of PR fampridine on self-perceived walking function reported here was higher than that reported by Hupperts et al., 15 perhaps due to the shorter treatment duration of 24 weeks. More than one-third of our patients reached a threshold of 6-and 8-point improvements in the MSWS-12 questionnaire after 2 years of treatment. Both thresholds are associated with clinically meaningful improvement of walking function. 15, 19, 20 Poor correlations between self-perceived walking function and clinical improvements during short-term treatment with PR fampridine as observed in the FAMPKIN core study are in line with previous results. 19 Longterm treatment with PR fampridine, in contrast, revealed significant correlations between changes in subjective ambulatory function and walking speed and endurance, implying that patients developed a better appreciation of the effects induced by PR fampridine over time. Significant effects of PR fampridine on MSWS-12 are underlined by patients' ability to correctly guess their allocation during double-blinded treatment arms.
The In contrast to previous long-term studies, 15 ,16 the present trial reassessed drug efficacy at regular time intervals. The regular baseline assessments minimized the effect of factors other than PR fampridine that may influence walking function over time (e.g., disease progression, change in concomitant treatment), allowing close and accurate monitoring of drug responsiveness in individual participants over more than 2 years.
A key constraint of the current trial is the limited number of patients, which is due to the intensity and logistics of such a comprehensive study design required to accurately track patients' individual responsiveness over time. Further long-term data of PR fampridine in PwMS are needed to confirm these results. A second limitation is that double-blind, long-term effects of PR fampridine were only assessed in half of the participants, i.e., those receiving PR fampridine at V5. The other half was randomized to be treated with placebo first before reinitiating treatment with PR fampridine at V6. Treatment effects in both groups were not different in any of the clinical walking tests.
This study demonstrates the good tolerability and significant persisting effects of long-term treatment with PR fampridine on ambulatory performance in PwMS over a period of more than 2 years. PR fampridine-induced walking improvements are perceived by most patients. Against a background of persisting improvements of walking function across all patients, longitudinal assessment of drug efficacy revealed remarkable changes in responsiveness to PR fampridine in some patients. In particular, those patients who showed a moderate to poor response in terms of walking improvement under PR fampridine at initial assessment were likely to improve their responsiveness to the drug over time, thus highlighting the necessity to regularly reassess the efficacy of PR fampridine on ambulatory function in PwMS. Persisting drug efficacy, combined with the fact that PR fampridine has also demonstrated beneficial effects in chronic progressive MS, 14, 16 where alternative treatment options to improve walking function are virtually absent, confirm PR fampridine as an important option in symptomatic, long-term treatment for gait-impaired PwMS.
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